Imatinib and beyond—the new CML study IVA randomized controlled comparison of imatinib vs imatinib/interferon-alpha vs imatinib/low-dose AraC vs imatinib after interferon-alpha failure in newly diagnosed chronic phase chronic myeloid leukemia

被引：0
|
作者：
U. Berger
G. Engelich
A. Reiter
A. Hochhaus
R. Hehlmann
机构：
[1] Universität Heidelberg,III. Medizinische Universitätsklinik, Klinikum Mannheim
来源：
Annals of Hematology | 2004年 / 83卷
关键词：
Chronic myeloid leukemia; Clinical trial; Imatinib; Interferon alpha; Stem cell transplantation;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：258 / 264
页数：6
相关论文
共 50 条
  • [1] Imatinib and beyond - the new CML study IV - A randomized controlled comparison of imatinib vs imatinib/interferon-alpha vs imatinib/low-dose AraC vs imatinib after interferon-alpha failure in newly diagnosed chronic phase chronic myeloid leukemia
    Berger, U
    Engelich, G
    Reiter, A
    Hochhaus, A
    Hehlmann, R
    ANNALS OF HEMATOLOGY, 2004, 83 (04) : 258 - 264
  • [2] Randomized controlled comparison of imatinib vs. imatinib/interferon α vs. imatinib/low-dose ara-C vs. imatinib after interferon α failure in newly diagnosed CML:: The German CML-Study IV -: Pilot phase.
    Berger, U
    Hochhaus, A
    Reiter, A
    Ehninger, G
    Fischer, T
    Gratwohl, A
    Hasford, J
    Heimpel, H
    Hossfeld, DK
    Kolb, HJ
    Krause, S
    Nerl, C
    Pralle, H
    Tobler, A
    Hehlmann, R
    BLOOD, 2003, 102 (11) : 904A - 904A
  • [3] Optimization of Interferon-Alpha and Imatinib Combination Therapy for Chronic Myeloid Leukemia: A Modeling Approach
    Bunimovich-Mendrazitsky, Svetlana
    Kronik, Natalie
    Vainstein, Vladimir
    ADVANCED THEORY AND SIMULATIONS, 2019, 2 (01)
  • [4] Cost-utility analysis of imatinib mesylate vs interferon-alpha in treating patients with chronic myeloid leukemia in chronic phase in Japan.
    Hasegawa, T
    Imai, F
    Miki, S
    BLOOD, 2002, 100 (11) : 872A - 872A
  • [5] Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
    O'Brien, SG
    Guilhot, F
    Larson, RA
    Gathmann, I
    Baccarani, M
    Cervantes, F
    Cornelissen, JJ
    Fischer, T
    Hochhaus, A
    Hughes, T
    Lechner, K
    Nielsen, JL
    Rousselot, P
    Reiffers, J
    Saglio, G
    Shepherd, J
    Simonsson, B
    Gratwohl, A
    Goldman, JM
    Kantarjian, H
    Taylor, K
    Verhoef, G
    Bolton, AE
    Capdeville, R
    Druker, BJ
    Durrant, S
    Schwarer, A
    Joske, D
    Seymour, J
    Grigg, A
    Ma, D
    Arthur, C
    Bradstock, K
    Joshua, D
    Louwagie, A
    Martiat, P
    Straetmans, N
    Bosly, A
    Shustik, C
    Lipton, J
    Forrest, D
    Walker, I
    Roy, DC
    Rubinger, M
    Bence-Bruckler, I
    Kovacs, M
    Turner, AR
    Birgens, H
    Bjerrum, O
    Facon, T
    NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (11): : 994 - 1004
  • [6] RANDOMIZED COMPARISON OF INTERFERON-ALPHA VS BUSULFAN - PROLONGATION OF SURVIVAL BY INTERFERON-ALPHA IN CHRONIC PHASE CML
    HEHLMANN, R
    HEIMPEL, H
    HASFORD, J
    KOLB, HJ
    HOSSFELD, DK
    HEINZE, B
    HOCHHAUS, A
    PRALLE, H
    QUEISSER, W
    LOFFLER, H
    ANSARI, H
    BLOOD, 1993, 82 (10) : A330 - A330
  • [7] Preliminary evaluation of the combination of imatinib mesylate (Gleevec) in combination with low dose interferon-alpha for the treatment of chronic phase CML.
    O'Dwyer, ME
    Mauro, MJ
    Kuyl, JM
    Paquette, R
    Sawyers, CL
    Druker, BJ
    BLOOD, 2001, 98 (11) : 846A - 846A
  • [8] Randomized Comparison of Imatinib 400 Mg Vs. Imatinib plus IFN Vs. Imatinib plus AraC Vs. Imatinib after IFN Vs. Imatinib 800 Mg: Optimized Treatment and Survival. Designed First Interim Analysis of the German CML Study IV
    Hehlmann, Ruediger
    Saussele, Susanne
    Lauseker, Michael
    Proetel, Ulrike
    Kovalevskaya, Elena
    Leitner, Armin
    Haferlach, Claudia
    Schlegelberger, Brigitte
    Mueller, Martin C.
    Hanfstein, Benjamin
    Pfirrmann, Markus
    Ehninger, Gerhard
    Fischer, Thomas
    Hasford, Joerg
    Hochhaus, Andreas
    Hossfeld, Dieter K.
    Kolb, Hans-Jochem
    Krause, Stefan W.
    Nerl, Christoph
    Pralle, Hans
    Gratwohl, Alois
    Tobler, Andreas
    Heimpel, Hermann
    BLOOD, 2008, 112 (11) : 75 - 75
  • [9] Upfront Combined Hydroxyurea and Imatinib versus Imatinib Monotherapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Randomized Controlled Trial
    Chetia, Rituparna
    Palepu, Sarika
    Dutta, Vikramjeet
    Bandyopadhyay, Arkapal
    Mathew, Anisha
    Vaniyath, Sudeep
    Bakliwal, Anamika
    Chattopadhyay, Debranjani
    Rajoreya, Ashok
    Dhamija, Puneet
    Naithani, Manisha
    Singh, Neha
    Nath, Uttam Kumar
    SOUTH ASIAN JOURNAL OF CANCER, 2024,
  • [10] Quality of life of patients with chronic phase chronic myeloid leukemia in the IRIS study of interferon-alpha plus Ara-C vs imatinib (STI571, Glivec®, Gleevec™).
    Hahn, EA
    Sorensen, MV
    Hudgens, SA
    Glendenning, GA
    BLOOD, 2002, 100 (11) : 94A - 94A
12345